Radiotherapy & Oncology
Volume 81, Issue 2 , Pages 163-167, November 2006

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

  • Atif J. Khan

      Affiliations

    • Department of Radiation Oncology,
    • ,
  • Par S. Mehta

      Affiliations

    • Department of Radiation Oncology,
    • ,
  • Thomas W. Zusag

      Affiliations

    • Department of Radiation Oncology,
    • ,
  • Philip D. Bonomi

      Affiliations

    • Department of Internal Medicine, Section of Medical Oncology, and,
    • ,
  • L. Penfield Faber

      Affiliations

    • Department of Surgery, Rush University Medical Center, Chicago, IL, USA
    • ,
  • Susan Shott

      Affiliations

    • Department of Internal Medicine, Section of Medical Oncology, and,
    • ,
  • Ross A. Abrams

      Affiliations

    • Department of Radiation Oncology,
    • Department of Internal Medicine, Section of Medical Oncology, and,
    • Corresponding Author InformationCorresponding author. Dr. Ross A. Abrams, Department of Radiation Oncology, Rush University Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612, USA.

Received 7 February 2006; received in revised form 30 August 2006; accepted 22 September 2006.

Abstract 

We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.

Keywords: Lung cancer, NSCLC, Oligometastasis, Oligometastases

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(06)00484-1

doi:10.1016/j.radonc.2006.09.006

Radiotherapy & Oncology
Volume 81, Issue 2 , Pages 163-167, November 2006

Article Tools

* Image Usage & Resolution